{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:18:55Z","timestamp":1785298735137,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Previous studies indicate that the efficacy and durability of a single AbobotulinumtoxinA (ABO) treatment for moderate to severe glabellar lines may be enhanced with increasing dose, while safety outcomes remain consistent with those of the licensed dose (50\u00a0U).<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>Evaluation of subject\u2010reported indicators of treatment efficacy, satisfaction, and psychological well\u2010being with ABO dose escalation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A Phase 2, 36\u2010week, multicenter, randomized, dose\u2010ranging, double\u2010blind, placebo\u2010controlled study was conducted in adults with moderate to severe glabellar lines. Subjects received a single ABO treatment, dosed at 50, 75, 100, or 125\u00a0U, or placebo. Efficacy endpoints comprised subject\u2010assessed improvement in line severity of \u22651\u2010grade from baseline at maximum frown, global aesthetic improvement scale (GAIS) grade, FACE\u2010Q\u2122 appraisal of lines, psychological well\u2010being and age, and subject satisfaction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 399\u00a0subjects (88.2% were female). Respective responder rates (\u22651\u2010grade improvement) with ABO 50\u2013125\u00a0U doses ranged between 96.3%\u2013100% at Week 4, 65.0%\u201367.9% at Week 24, and 33.8%\u201344.4% at Week 36. GAIS responder rate and FACE\u2010Q appraisal of lines showed a similar pattern of change. Satisfaction was high and psychological well\u2010being was improved from Week 4 through Week 36, with natural, youthful, and refreshed appearance reported for all ABO doses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A single ABO treatment (dosed at 50\u2013125\u00a0U) provided significant and sustained improvements in glabellar line severity over durations up to 36\u00a0weeks, versus placebo. Treatment satisfaction was high with all doses. Participants reported natural and youthful appearance, alongside improvements in psychological well\u2010being.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.14906","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T08:27:59Z","timestamp":1646900879000},"page":"2407-2416","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Subject satisfaction and psychological well\u2010being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines"],"prefix":"10.1111","volume":"21","author":[{"given":"Steven","family":"Dayan","sequence":"first","affiliation":[{"name":"DeNova Research  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Joseph","sequence":"additional","affiliation":[{"name":"Clinical Testing of Beverly Hills  Encino California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Moradi","sequence":"additional","affiliation":[{"name":"Moradi M.D.  Vista California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Paul","family":"Lorenc","sequence":"additional","affiliation":[{"name":"Lorenc Aesthetic Plastic Surgery Center  New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Coleman","sequence":"additional","affiliation":[{"name":"Etre Cosmetic Dermatology and Laser Center  New Orleans Louisina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glynis","family":"Ablon","sequence":"additional","affiliation":[{"name":"Ablon Skin Institute and Research Center  Manhattan Beach California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7305-6898","authenticated-orcid":false,"given":"Joely","family":"Kaufman\u2010Janette","sequence":"additional","affiliation":[{"name":"Skin Research Institute, LLC, Coral Gables  Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Ellen","family":"Cox","sequence":"additional","affiliation":[{"name":"Aesthetic Solutions, PA  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Campbell","sequence":"additional","affiliation":[{"name":"Quintessa Aesthetic Center \u2013 EthiQ2 Research, LLC  Mequon Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Munavalli","sequence":"additional","affiliation":[{"name":"Dermatology, Laser &amp; Vein Specialists of the Carolinas PLLC  Charlotte North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Prygova","sequence":"additional","affiliation":[{"name":"Galderma  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"The Aesthetic Society when citing statistical data. Aesthetic plastic surgery national databank statistics 2020. Available at:https:\/\/cdn.surgery.org\/media\/statistics\/aestheticplasticsurgerynationaldatabank\u20102020stats.pdf[accessed January 2022]"},{"issue":"5","key":"e_1_2_11_3_1","first-page":"101","article-title":"Treating glabellar lines with botulinum toxin type A\u2010hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction","volume":"26","author":"Boulle K","year":"2010","journal-title":"Clin Interv Aging"},{"key":"e_1_2_11_4_1","unstructured":"Ipsen Biopharmaceuticals Inc.Dysport\u00ae(abobotulinumtoxinA) for injection for intramuscular use. Prescribing information. Available at:https:\/\/www.ipsen.com\/websites\/Ipsen_Online\/wp\u2010content\/uploads\/sites\/9\/2019\/01\/21084019\/Dysport_Full_Prescribing_Information.pdf[accessed January 2022]"},{"key":"e_1_2_11_5_1","unstructured":"Galderma UK.Azzalure 125 Speywood units powder for solution for injection. Summary of product characteristics. September 2021. Available at:https:\/\/www.medicines.org.uk\/emc\/product\/6584[accessed January 2022]."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins13070494"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-018-1200-4"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002013"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001926"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000805"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001679"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2009.01235.x"},{"issue":"2","key":"e_1_2_11_13_1","first-page":"E69","article-title":"Patient satisfaction with abobotulinumtoxinA for aesthetic use in the upper face: a systematic literature review and post\u2010hoc analysis of the APPEAL study","volume":"14","author":"Smit R","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002846"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001940"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjv244"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2010.01795.x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjx179"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000000895"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamafacial.2016.0001"},{"issue":"12","key":"e_1_2_11_21_1","first-page":"1544","article-title":"Does increasing the dose of abobotulinumtoxinA impact the duration of effectiveness for the treatment of moderate to severe glabellar lines?","volume":"15","author":"Joseph JH","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6263"},{"key":"e_1_2_11_23_1","unstructured":"FACE\u2010Q | Aestherics\u00a9 A guide for researcher and clinicians. 2015. Available at:http:\/\/qportfolio.org\/wp\u2010content\/uploads\/2018\/08\/FACE\u2010Q\u2010AESTHETICS\u2010USER\u2010GUIDE.pdf[accessed January 2022]"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1090820X13510170"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjz248"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.5454"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.14906","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jocd.14906","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.14906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T22:30:38Z","timestamp":1692829838000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.14906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/jocd.14906"],"URL":"https:\/\/doi.org\/10.1111\/jocd.14906","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"assertion":[{"value":"2022-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}